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Tumor necrosis factor alpha (TNFa), a pleiotropic cytokine,
plays important inflammatory roles in renal diseases such as
lupus nephritis, anti-neutrophil cytoplasmic antibody
(ANCA)-associated glomerulonephritis and renal allograft
rejection. However, TNFa also plays critical
immunoregulatory roles that are required to maintain
immune homeostasis. These complex biological functions of
TNFa are orchestrated by its two receptors, TNFR1 and
TNFR2. For example, TNFR2 promotes leukocyte infiltration
and tissue injury in an animal model of immune
complex–mediated glomerulonephritis. On the other hand,
TNFR1 plays an immunoregulatory function in a murine lupus
model with a deficiency in this receptor that leads to more
severe autoimmune symptoms. In humans, proinflammatory
and immunoregulatory roles for TNFa are strikingly
illustrated in patients on anti-TNFa medications: These
treatments are greatly beneficial in certain inflammatory
diseases such as rheumatoid arthritis but, on the other hand,
are also associated with the induction of autoimmune lupus-
like syndromes and enhanced autoimmunity in multiple
sclerosis patients. The indication for anti-TNFa treatments in
renal inflammatory diseases is still under discussion. Ongoing
clinical trials may help to clarify the potential benefit of such
treatments in lupus nephritis and ANCA-associated
glomerulonephritis. Overall, the complex biology of TNFa is
not fully understood. A greater understanding of the function
of its receptors may provide a framework to understand its
contrasting proinflammatory and immunoregulatory
functions. This may lead the development of new, more
specific anti-inflammatory drugs.
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Tumor necrosis factor alpha (TNFa) is a pleiotropic cytokine
widely implicated in immune regulation. Mainly produced
by activated macrophages, it is most often associated with
proinflammatory properties and plays a pivotal role in innate
and adaptive immunity, especially in host defense mechan-
isms against intracellular bacteria.1–3
First described for its capacity to induce hemorrhagic
necrosis in mouse tumor,4,5 TNFa is now more recognized
for its role in inflammatory and autoimmune diseases such as
sepsis, rheumatoid arthritis, inflammatory bowel diseases,
psoriasis, and multiple sclerosis. The development of TNFa
neutralizing treatments remarkably improved the prognosis
of patients with rheumatoid arthritis,6,7 severe Crohn’s
disease,8 psoriasis, and psoriatic arthritis9–11 or ankylosing
spondylitis12,13 and has rapidly become a first choice for
treatment of many severe cases of these diseases.
More recently, accumulating evidence suggests that TNFa
also plays an important immunoregulatory role and directly
participates in the maintenance of immune homeostasis. It is
thus not surprising that anti-TNFa treatments are not the
panacea for inflammatory conditions, as it may be associated
with the emergence of autoimmune symptoms such as the
induction of autoantibodies (for example anti-dsDNA
antibodies in up to 14% of rheumatoid arthritis patients
treated with infliximab14,15), inflammatory neurological
events,15 and lupus syndromes.14,16,17 Moreover, different
clinical trials have failed to report a beneficial effect in
patients with sepsis, a condition also directly related to
TNFa.18–21 Indeed, increased mortality in a subgroup of
patients suffering from gram-positive sepsis has even raised
concerns about the safety of these medications.22 In addition,
a controlled clinical trial of TNFa blockade in multiple
sclerosis has shown a worsening of the symptoms in many
patients receiving the anti-TNFa treatment associated with a
non-significant trend of increased magnetic resonance
imaging lesions23 also reported in another study.24 This
underscores the complexity of TNFa biology in inflamma-
tory diseases and emphasizes the need to better understand
the role of TNFa and its receptors in different inflammatory
conditions. The net effect of TNFa is a balance between its
proinflammatory and immunosuppressive function, which is
determined by the cellular microenvironment and differs, for
instance, between the early and late phases of inflammation.
r e v i e w http://www.kidney-international.org
& 2009 International Society of Nephrology
Received 3 February 2009; accepted 24 February 2009; published online
13 May 2009
Correspondence: Thomas Ernandez, Brigham and Women’s Hospital and
Harvard Medical School, 77 Avenue Louis Pasteur NRB 752, Boston, MA
02115, USA. E-mail: ternandez@rics.bwh.harvard.edu
262 Kidney International (2009) 76, 262–276
TNFa biology thus needs to be considered in the specific
context of each inflammatory disease and involved tissue.
Indeed, such dualistic immunosuppressive-proinflammatory
roles have been described for other cytokines such as IL-12
and INFg.25–27
The kidney is frequently affected in inflammatory and
autoimmune diseases, and TNFa has been largely implicated
in the inflammatory cascade leading to renal injury. The
contrasting proinflammatory and immunosuppressive roles
of TNFa in the kidney are evident in experimental models of
lupus nephritis,25,28–30 and anti-TNFa treatments have shown
promising results in animal models of glomerulonephritis.
However, their efficiency in human immune complex-
mediated renal diseases is currently still in question. For
instance, small open-label clinical trials31–33 have shown
promising results in anti-neutrophil cytoplasmic antibody
(ANCA)-associated vasculitis nephritis contrasting with the
failure of etanercept, a TNFa decoy receptor, in a recent
larger randomized controlled trial in Wegener granuloma-
tosis.34 In lupus nephritis, infliximab, an anti-TNFa anti-
body, may also have some beneficial effects, and the results of
an ongoing controlled clinical trial are forthcoming.32,35–37
The effect of etanercept in the treatment of lupus nephritis is
also underway.38 In this review, we will describe the basic
biology underlying the antagonistic effects of TNFa and
discuss the role of TNFa and its receptors, as well as the
future potential of anti-TNFa treatments, in renal inflam-
matory diseases.
TNFa AND ITS RECEPTORS
TNFa is initially expressed as a functional 26-kDa homo-
trimer transmembrane protein.39–42 It may be cleaved by a
metalloproteinase, the TNFa-converting enzyme (also named
ADAM-17), and is released into the circulation as a
functional 17-kDa soluble form.43,44 Although TNFa is
mostly expressed and secreted by hematopoietic cells, it
may be expressed by tissue resident cells. In normal kidney,
TNFa is usually not detected,45,46 despite some data to the
contrary.47 However, most renal cells produce TNFa after
stimulation. In vitro stimulation of mesangial cells with
lipopolysaccharide (LPS)48,49 or soluble aggregates of IgG50
upregulates TNFa. Tubular epithelial cells also express TNFa
after treatment with IL-1a or LPS.51,52 In vivo epithelial cells
generate TNFa after LPS exposure49,52 and podocytes express
TNFa during membranous nephropathy.53
In vivo, the TNFa expression pattern in the kidney seems
to be related to the primary compartment injured. For
instance, in renal ischemia-reperfusion injury,54 renal ob-
struction,55 or acute renal allograft rejection,45 TNFa is
mostly produced by tubular cells. On the other hand, TNFa
expression is preferentially localized in glomerular cells in
IgA nephropathy,46 minimal change disease,46 idiopathic
membranous nephropathy,46,53 or proliferative and membra-
nous lupus nephropathy.56,57 In vasculitis-associated nephri-
tis, in which inflammation involves several kidney
compartments, TNFa is expressed in resident glomerular
cells, endothelial cells, interstitia and, to a lesser extent,
tubular cells.58
The function of TNFa is relayed by two structurally
distinct receptors, tumor necrosis factor receptor (TNFR)1
(TNFRSF1A, p55, CD120a) and TNFR2 (TNFRSF1B, p75,
CD120b). They belong to the TNFa receptor superfamily, a
group of type I transmembrane glycoprotein, characterized
by a conserved homologous cysteine-rich domain in their
extracellular region. Similar to TNFa, they form non-
covalently bound homotrimers at the surface.59,60 TNFR1
and TNFR2 are only 28% homologous mostly in their
extracellular domain and share no homology in their
intracellular regions. The cytoplasmic domains in both
receptors are devoid of intrinsic enzyme activity and need
to recruit cytosolic intermediate proteins to transduce
signals.60
The two TNFRs have different affinity for the soluble and
membrane-bound forms of TNFa. TNFR1 binds equally well
to both forms of TNFa, whereas TNFR2 has a higher affinity
for the membrane-bound form and a low-binding capacity
for the soluble form of TNFa.60 Interestingly, although
soluble murine TNFa binds equally well to both human
TNFRs, the human soluble TNFa can bind only to mouse
TNFR1.61
The physiological relevance of the different affinities of
TNFR2 for membranous versus soluble TNFa remains largely
unclear. As the transmembrane form of TNFa is biologically
active,40 this may suggest a preferential role for TNFR2
during cell–cell interactions.62 For instance, TNFa–TNFR2
interactions seem to be critical in the generation of FasL-
dependent cytolytic T-cell effector pathways in murine
hepatic viral infection.63 TNFa–TNFR2 interactions also play
a prominent role in the priming of CD4þ T cells in a murine
model of intestinal graft-versus-host disease.64 The specific
cell–cell TNFa–TNFR2 interaction has also a pivotal function
in the maturation of dendritic cells mediated by natural killer
cells in mice.65 In humans, CD8þ T-cell apoptosis seems to
be mediated specifically by the interaction between membra-
nous TNFa and TNFR2, independently of TNFR1.66
Tumor necrosis factor receptor 1 is located mostly
intracellularly in the trans-Golgi network with a smaller
subset located at the cell surface.67,68 The specific function of
the Golgi location of the TNFR1 remains unresolved, but it
may serve as a reservoir to reconstitute the plasma membrane
TNFR1 pool, which is shed and internalized after binding its
ligand.67 The possibility that endogenously synthesized
intracellular TNFa interacts with Golgi-associated TNFR1
has also been suggested.68–70 Nevertheless, the interaction of
TNFR1 with TRADD (TNF receptor-associated death
domain protein), a proximal adapter molecule essential for
transduction of TNFR1 signals, occurs only at the plasma
membrane level, suggesting that surface TNFR1 is function-
ally more significant than the Golgi pool of the receptor.68
Both TNFRs are regulated differently and show different
expression patterns. TNFR1 is widely expressed in many
different cell types, whereas TNFR2 is preferentially expressed
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in hematopoietic cells.71 TNFR1 expression is under the
control of a ‘housekeeping’-type promoter,72–74 which is
consistent with the finding that its expression is less
modulated than TNFR2. In the normal kidney, TNFR1 is
expressed in the glomeruli, but not in the tubular compart-
ment.45 Its expression is increased in inflammatory kidney
diseases such as human lupus nephritis (WHO class III/IV),
but not in purely mesangial or membranous lupus nephritis
(WHO class II and V) or in idiopathic membranous
nephropathy.47 In acute allograft rejection, TNFR1 expres-
sion in glomeruli is lost; however, infiltrating leukocytes in
the interstitium, such as lymphocytes and macrophages,
express TNFR1 highly.45
By contrast, TNFR2 is usually not expressed in normal
kidney,45,75 although it is present at low levels in isolated
glomerular cells of normal kidney biopsies.47,76 In response
to renal injury, TNFR2 expression is induced both in
interstitial post-capillary venules and in glomeruli in murine
nephrotoxic serum nephritis and a model of immunecomplex-
mediated glomerulonephritis.75 It is upregulated in tubular
cells in acute renal allograft rejection,45,76 acute tubular
necrosis,76 and renal obstruction.75 Interestingly, TNFR2
expression is increased in renal inflammation in a pattern
that is similar to TNFa, which suggests a regulation of
TNFR2 by its ligand, possibly through an autocrine or
paracrine pathway. This is supported by experimental data:
in a murine model of cisplatin-induced renal injury, TNFR2
mRNA upregulation observed in a renal tissue sample in a
wild-type mouse was blunted in TNFa-deficient mice.77
Another report described increased TNFR2 mRNA level in
tubular cells (but not in glomerular cells) of human
kidney culture samples after TNFR2 activation through a
specific protein agonist (mutein).76 The transcriptional
regulation of TNFR2 can be attributed to its large promoter,
which contains a variety of transcriptional factor-binding
sites, including those for NFkB, AP-1, IRF-1, and GAS,71
suggesting that the expression of TNFR2 may be finely
regulated and highly variable depending on the micro-
environment. Moreover, similar to TNFa mRNA,78,79 TNFR2
mRNA contains a large 30 untranslated region (more than
2000 bp in both humans and mice), which may play a role
in post-transcriptional regulation of TNFR2 protein.80
Similar to TNFa, both TNFRs can be cleaved to a
functional soluble form59,60 by the common metalloprotei-
nase TNFa-converting enzyme. The soluble receptors may
also be produced from a spliced mRNA variant devoid of the
transmembrane domain.81 Soluble TNFRs may play a critical
role in regulating the inflammatory response by binding and
eventually neutralizing free TNFa.82–85 Experimentally,
administration of a soluble form of TNFR1 protects rats
against glomerular injury in heterologous nephrotoxic
nephritis, an animal model of immunecomplex-mediated
glomerulonephritis.86,87 In humans, the clinical significance of
receptor cleavage is underscored by the existence of the TNFa
receptor-1-associated periodic syndrome caused by an auto-
somal dominant genetic defect in the extracellular domain of
TNFR1 that prevents its cleavage.88 TNFa receptor-1-asso-
ciated periodic syndrome patients develop a fluctuating
autoinflammatory disease associated with recurrent periodic
fever episodes over months or years without apparent
infections, skin inflammatory lesions, and occasionally
secondary amyloidosis without apparent infections.43
SIGNALING PATHWAYS OF TNFR1 AND TNFR2
The main structural difference between TNFR1 and TNFR2 is
the presence of a death domain (DD) in the cytoplasmic
domain of TNFR1 (Figure 1).89,90 In unactivated TNFR1, the
DD is occupied by the SODD (silencer of DD protein), which
prevents ligand-independent activation of the receptor. The
binding of TNFa on TNFR1 induces the release of SODD and
allows the TRADD to interact with the DD.60 TRADD is an
essential partner of TNFR1 for signal transduction91 and can
recruit the downstream adapter molecule FADD (fas-
associated death domain), which initiates the caspase
pathway responsible for apoptotic cell death. On the other
hand, TRADD is also able to interact directly with the TNF
receptor-associated factor 2 protein (TRAF2), which in turn
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Figure 1 | TNFa receptor-signaling pathways. SODD, silencer of
death domain protein; TRADD, TNF receptor-associated death
domain protein; TRAF2, TNF receptor-associated factor 2 protein;
Etk/bmx, endothelial/epithelial tyrosine kinase; FADD, Fas-
associated death domain protein; RIP, receptor interacting
protein; JNK, c-Jun N-terminal kinase.
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can trigger the activation of pathways, such as NFkB,92 AP-1,
c-Jun N-terminal kinase stress kinases, and p38MAPK,
mostly implicated in cell survival signaling and inflammatory
responses (reviewed in3,60). The receptor-interacting protein
(RIP) is another important signaling intermediate interacting
with TRAF2 and plays, for instance, a critical role in TNFa
mediated lymphocyte apoptosis (cf below). Many other
intermediate proteins, including inhibitory adapter proteins
such as inhibitors of apoptosis protein family, also finely
modulate the signaling of both TNFa receptors3,60 and set the
balance between apoptosis induction and cell proliferation
signal. More details of these pathways can be found in the
recent review of MacEwan.60
The signaling pathway engaged by TNFR2 is much less
well understood. The cytosolic tail of TNFR2 directly bind
TRAF2, which in turn mediates most of the signaling events
induced by this receptor. For instance, the in vitro over-
expression of TNFR2 activates NFkB through a TRAF2-
dependent mechanism,93 but through a signaling mechanism
distinct from those involved in TNFR1–NFkB activation.94
However, endogenous TNFR2 in cell types such as endothe-
lial cells was not able to engage this pathway alone,95 and may
require co-activator signals. TNFR2 is also able to induce
c-Jun N-terminal kinase and p38MAPK pathways and to
interact with RIP through TRAF2.3,60 Interestingly, a
secondary indirect TRAF2-binding site in the TNFR2
cytoplasmic domain has been recently described. This novel
interaction seems to regulate the capacity of TNFR2 to
engage TRAF2, and thereby modulate its signaling capacity.96
As shown for TNFR1, TNFR2 is able to induce apoptosis,
possibly through a TNFR2–TRAF2–FADD interaction.97
A specific novel TNFR2-signaling pathway has been
recently implicated in angiogenesis regulation.98,99 TNFR2
interacts directly with the endothelial/epithelial tyrosine
kinase (Etk/bmx) independently of TRAF2100 and plays a
critical role in VEGFR2 signal transduction in endothelial
cells.101 Etk then activates the phosphatidylinositol 3 kinase-
Akt pathway,100 which may contribute to the TNFa-induced
cell proliferation and possibly tissue repair mechanisms. It is
noteworthy that phosphorylation of Etk is a specific indicator
of TNFR2 signaling.76 Despite these in vitro data, the
significance of TNFR2 signaling in vivo remains to be
clarified.
Although TNFR1 signaling is widely implicated in
inflammatory responses and is the hallmark of sepsis,1,102
the role of TNFR2 and its signaling partners in inflammation
is unclear. There is, however, accumulating experimental
evidence suggesting that TNFR2 plays a role in inflammatory
responses, independently of TNFR1. For instance, over-
expression of human TNFR2 in transgenic mice is associated
with increased lethality in the context of LPS exposure and
these mice develop a spontaneous diffuse inflammatory
phenotype independently of TNFR1 expression.103 More
recently, our group has shown a critical role for this receptor
in renal injury in a murine model of immune complex
glomerulonephritis.75
GENERIC ROLES OF TNFa IN INFLAMMATION
Proinflammatory roles
TNFa is a key player in innate and adaptive immunity. Its
proinflammatory properties are well described and mainly
lead to the activation and recruitment of inflammatory cells
to the site of injury (Table 1). TNFa induces, for instance, the
local activation of vascular endothelium, the release of nitric
oxide and thereby local vasodilation, an increase of vascular
permeability, the expression of adhesion molecules on the
endothelial cells (ICAM-1, VCAM-1, E-Selectin), the release
of other cytokines and chemokines (MCP-1, RANTES, IL-1,
IL-6, IL-8), and the expression of class I and II major
histocompatibility molecules.1,2,104,105
As most of these mechanisms may be triggered by the
soluble form of TNFa, the specific role of its transmembrane
form remains unclear. However, experiments with engineered
transgenic mice offer some clues. Mice expressing only a
mutated non-cleavable transmembrane form of the TNFa are
fully protected against endotoxic shock,41 but retain cell-
mediated immunity against Mycobacterium bovis bacillus
Calmette-Guerin infection.106 On the other hand, over-
expression of a non-cleavable form of TNFa in mice induces
an inflammatory phenotype characterized mainly by severe
arthritis.107,108 Moreover, the constitutive endothelial-specific
overexpression of this non-cleavable form of TNFa in mice
induces a diffuse inflammatory phenotype with chronic
leukocyte infiltration in the kidneys, liver, and lungs, together
Table 1 | Proinflammatory versus immunoregulatory
properties of TNFa
Proinflammatory Immunoregulatory
Blood vessels activation Organogenesis of secondary
lymphoid organs
K Vasodilation
K Increase of vascular permeability
K Expression of adhesion molecules:
ICAM-1, VCAM-1, E-Selectin
K Formation and
maturation of germinal
centers
K Maturation of follicular
dendritic cells
Cell activation Maintenance of central and
peripheral tolerance
K Activation/priming of leukocytes
K Induction of expression of
MHC I and II
K Proliferation of fibroblasts and
mesangial cells
K Thymocyte apoptosis
K Activation induced
T cell apoptosis
K Induction of C1q and
serum amyloid P
components
Induction of chemokines, cytokines, and
other inflammatory mediators
Immunosuppression
K Release of cytokines and
chemokines: MCP-1, RANTES, IL-1,
IL-6, IL-8, complement component C3
K Release of prostaglandins,
leukotrienes, nitric oxide, and
reactive oxygen species
K Upregulation of matrix
metalloproteinases
K Downregulation of
TCR-signaling and T-cell
responsiveness
K B-cell sensitization to
FAS-mediated
apoptosis
ICAM-1, intercellular adhesion molecule 1; IL, interleukin; MCP-1, monocyte
chemoattractant protein-1; RANTES, regulated upon activation, normal T-cell
expressed, and secreted (CCL5); TCR, T-cell receptor; VCAM-1, vascular cell adhesion
molecule-1.
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with an upregulation of the adhesion molecules ICAM-1 and
VCAM-1 in the endothelium of the liver and the kidneys.109
Although the underlying mechanisms for these phenotypes
remain unclear, these data do suggest that TNFa cleavage
may be important in downregulating local TNFa-induced
inflammatory events.
In the kidney, TNFa may be directly involved in renal
injury. Although monocytes/macrophages remain the main
source of TNFa, the local production of TNFa by stimulated
intrinsic renal cells seems to be functionally more relevant in
renal inflammation.110 This is supported by the observation
that these cells may be the source and target of TNF. TNFa
expression, induced in human intrinsic renal cells or tubular
cells in different inflammatory conditions,45,46,56,57 preferen-
tially target mesangial cells to produce inflammatory
mediators implicated in renal injury, such as M-CSF,
MCP1, GM-CSF, IL-6, prostaglandins E2, platelet-activating
factor, reactive oxygen metabolites, tissue factor, and TNFa
itself through an autocrine pathway.111–115 Glomerular
endothelial cells are also a target of TNFa, which induces
the expression of endothelial VCAM-1 and E-Selectin.115
Moreover, TNFa amplifies the production of the third
component of the complement cascade by endothelial
cells,116 which plays a critical role in the pathogenesis of
murine immune complex-mediated glomerulonephri-
tis.117,118
Immunoregulatory roles
TNFa also shows critical immunoregulatory functions in
both innate and adaptive immunity (Table 1). It is, for
instance, an important mediator of lymphoid organogen-
esis.2,3 TNFa-deficient mice form lymphoid nodes, but with
an aberrant architecture devoid of a germinal center and
follicular dendritic cells.119 This seems to be mediated mostly
by TNFR1,120 as TNFR2-deficient mice present with normal
lymphoid tissue. It is thus not surprising that TNFa possesses
immunoregulatory functions, which may be critical in the
maintenance of immune tolerance. As already mentioned, the
importance of its immunosuppressive role is strikingly
underscored by the autoimmune syndromes observed in
patients treated with anti-TNFa medications,14–17 and
particularly by the failure of the TNFa blockade in multiple
sclerosis with a higher number and rate of clinical
exacerbations of disease observed in some treated pa-
tients.23,24
In animal models, diminished expression of TNFa has been
associated with the emergence of autoimmune diseases.78
For example, in experimental autoimmune encephalomyeli-
tis, an animal model of multiple sclerosis, TNFa-deficient
mice develop more severe disease than wild-type or TNFa-
heterozygous animals.121 In a specific mouse strain (129/SV)
usually resistant to this model, TNFa deficiency leads
to the development of neurological symptoms. Administra-
tion of recombinant human TNFa in TNFa-deficient mice
prevents the occurrence of the disease or reverses symptoms
when administered 10 days after the induction of the
disease.121 These observations are supported by two other
publications showing exacerbated disease in TNFR2-
deficient mice, suggesting a pivotal role for TNFa–TNFR2
in controlling the emergence of central nervous system
autoreactivity.122,123 Finally, a third report emphasizes the
immunosuppressor role of TNFa–TNFR2 in this model: in
the absence of TNFa, but independently of TNFR1, myelin-
specific T-cell autoreactivity fails to regress as normally
observed in wild-type mice, and memory T cells expansion is
prolonged.124
Besides brain inflammation, this immunoregulatory role
of TNFa is observed in other animal inflammatory models,
suggesting a generic immunoregulatory function for TNFa.
For instance, nonobese diabetic mice, which spontaneously
develop diabetes and are used as a model of human
autoimmune insulin-dependent diabetes mellitus, present
three to five times lower TNFa production capacity
compared with another close mouse strain (SWR), suggesting
that lower production of TNFa may trigger autoimmunity
emergence.125 Indeed, they show significant improvement in
disease indices after intraperitoneal injections of recombinant
murine TNFa.125 A similar effect of exogenous administra-
tion of TNFa in New Zealand lupus-prone mice has been
observed.30 This immunoregulatory role of TNFa in the
lupus model will be discussed in detail below.
At a cellular level, several mechanisms of the immuno-
regulatory effects of TNFa have been proposed, primarily
related to T-cell homeostasis.25 TNFa plays a critical role in
T-cell regulation.126 Activated T cells principally express
TNFR2, which is mainly implicated in T cell TNFa-mediated
apoptosis.66,127 This process is directly regulated by the
intermediate signaling protein kinase RIP, which acts as a
‘molecular switch’ between cell death and survival. Although
RIP plays a protective role in TNFR2-mediated apoptosis of
thymocytes,128 the loss of expression of RIP by activated
peripheral T cells sensitizes these cells to TNFR2-mediated
apoptosis.129 TNFR1 is, however, also able to induce
apoptosis of activated T cells.130,131 The role of TNFa in
T-cell homeostasis has been convincingly shown in vivo:
transgenic overexpression of TNFa specifically in pancreatic
islet prevents diabetes in nonobese diabetic mice by
inhibiting the development of auto-reactivity132 through
the induction of CD4þ T-cell peripheral tolerance.133 By
inducing apoptosis of thymocytes and mature T cells, TNFa
is thus directly implicated in maintaining central as well as
peripheral tolerance. Moreover, apoptosis of activated T cells
mediated by TNFa may be a critical step in the termination
of inflammatory processes.
TNFa may also modulate the level of T-cell responsive-
ness. In a murine model, chronic exposure to TNFa
downregulates T-cell receptor signaling and lowers T-cell
responsiveness to antigenic stimulation in vitro and in
vivo.134,135 Other data suggest that TNFa also plays a role
in B-cell homeostasis. For instance, TNFa may prevent B-cell
apoptosis in T cell areas, but it also sensitizes them to
Fas-mediated apoptosis at a later stage of differentiation,
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thereby offering another protective mechanism against
autoimmunity emergence.136 This is also illustrated by the
impaired B-cell development and the striking absence of B220þ
B cells in mice overexpressing human TNFR2.103 An alternative
mechanism indirectly mediated by TNFa for maintenance of
central tolerance has also been proposed.25 TNFa is
important in the production of acute serum proteins in
inflammation, such as C1q and serum amyloid P component,
which have been implicated in the clearance of apoptotic cells
and their potentially autoreactive contents. Indeed, C1q and
serum amyloid P component-deficient mice develop auto-
antibodies and lupus nephritis.137–139 Reduced production or
function of TNFa may limit the release of these acute phase
mediators and thereby facilitate autoimmunity.
TNFa IN INFLAMMATORY KIDNEY DISEASES
Immune complex-mediated glomerulonephritis
TNFa is largely implicated in renal inflammation and
glomerular damage induced by immune complex deposition.
Renal expression of TNFa is upregulated in both mice and
human glomerulonephritis,46,47,53,57 and correlates with an
increase in serum and urine levels of TNFa.57,140 The
functional proinflammatory role of TNFa has been shown
in experimental models of immune complex-mediated
glomerulonephritis, in which TNFa deficiency or TNFa
blockade treatments clearly offer protection against glomer-
ular injury. For instance, in the well described accelerated
nephrotoxic serum nephritis model, systemic administration
of TNFa exacerbated glomerular injury in rats.141 By
contrast, pentoxifylline treatment in a similar model, which
interferes with the endogenous production of TNFa, has
beneficial effects. It limits renal injury if administered
preventively or started at the peak of the disease, albeit to a
lesser extent.142 Anti-TNFa treatments also offer some
protection against this model of glomerulonephritis in
rats.86,143,144 Similarly, TNFa-deficient mice are partially
protected against glomerular injury (proteinuria and cres-
centic lesions) and present with lower renal infiltration of T
cells and neutrophils.145,146 Moreover, using bone marrow
chimeric mice, it has been convincingly shown that intrinsic
renal cells are the principal source of TNFa responsible for
glomerular damage in this model.110
A recent publication by our group offers new insights on
the respective role of each TNFR in immune complex-
mediated glomerulonephritis.75 When TNFR1- and TNFR2-
deficient mice were subjected to the accelerated nephrotoxic
nephritis model and renal damage was compared with wild-
type animals, TNFR1-deficient mice presented with a delay in
disease that was associated with a reduction in the adaptive
humoral response (that is, lower circulating mouse anti-
rabbit IgG after rabbit IgG immunization). This may be
explained by impaired T-cell priming required for B-cell
activation and proliferation, as earlier reports have shown
that TNFR1 is required for T-cell priming124 and the delayed
type hypersensitivity response.147 However, at a later time
point, TNFR1-deficient mice presented with glomerular
damage to a similar extent as did wild-type mice, but with
a marked increase in lymphocytic infiltration in renal tissue,
which may explain the development of glomerular damage
despite the impaired adaptive immune response in these
animals. This was linked to a decrease in T-cell apoptosis,
which may be mediated by TNFR1 as shown by other
groups.130,131 More strikingly, TNFR2-deficient mice were
completely protected against disease despite a proven
preservation of their humoral response (circulating mouse
anti-rabbit IgG comparable with wild-type mice) and an
efficient delayed type hypersensitivity response as reported
earlier.147 The reduction in renal injury was associated with a
marked decrease in C3 glomerular deposition as well as in
nearly absent renal leukocyte infiltration. As complement
activation is associated with glomerular damage in this model
of glomerulonephritis,148–150 a link between TNFR2 and
complement activation may in part explain this phenotype.
TNFR2-deficient mice also presented with a defect in renal
leukocyte recruitment, which is supported by another report
showing a decrease of renal leukocyte infiltration in TNFR2-
deficient mice subjected to cisplatin-induced renal injury.77
This is possibly related to a significantly lower expression of
ICAM-1 in these mice compared with wild-type or TNFR1-
deficient animals77 or with a defect in the chemoattractant
function of the complement cascade. Moreover, bone marrow
chimeric experiments identified that TNFR2 specifically
expressed on intrinsic renal cells, possibly glomerular
endothelial cells, are the critical event leading to glomerular
injury in this glomerulonephritis model.75 Overall, our work
shows the critical selective proinflammatory role of TNFR2 in
mediating renal injury in glomerular disease.
Lupus nephritis
A large body of evidence implicates TNFa in systemic lupus
nephritis. As reviewed recently,36 the role of TNFa in this
disease is ambiguous as it plays both proinflammatory and
immunoregulatory roles. In lupus nephritis, the role of TNFa
may be biphasic. In the initiation phase of autoimmune
disease, it may have a critical immunosuppressive function,
but later in the evolution of the disease, it may orchestrate the
inflammatory process responsible for tissue injury. Indeed, in
the classic animal models of systemic lupus erythematosus
(SLE), (New Zealand black (NZB)New Zealand white
(NZW))F1 and MRL-lpr/lpr, TNFa plays an immunosup-
pressive role by inhibiting the emergence of autoreactivity,
whereas in the latter phase, TNFa leads to end-organ
damage, in particular lupus nephritis.
TNFa levels are very variable in SLE patients and in
different animal models. The role of TNFa in SLE is difficult
to study because of the complex genetics of this disease and
the tight linkage between the TNFa gene and the major
histocompatibility complex locus.151 A case in point is that
different HLA genotypes in patients associated with both low
and high levels of circulating TNFa have an increase in
incidence of SLE.25,152 Consistent with these findings, the
two principal experimental models of SLE in mice,
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(NZBNZW)F1 and MRL-lpr/lpr, have low and high levels
of the cytokine, respectively.
Aside from the major histocompatibility complex genetic
susceptibility to autoimmune disease of NZB mice, NZW
mice in the (NZBNZW)F1 model have genetic aberra-
tions in the untranslated region of the TNFa mRNA that
reduce its stability and thus the translation efficiency of
the protein.29 NZW mice therefore show a reduction of
50–60% of TNFa production under stimulated conditions
(that is, in vitro LPS treatment of peritoneal macro-
phages).25,30 Thus, a reduction of TNFa production may be
linked to the emergence of autoimmunity in susceptible
genetic backgrounds. This is supported by earlier studies
showing that replacement therapy of exogenous recombinant
TNFa to (NZBNZW)F1 mice delayed the development of
lupus nephritis without affecting B cell and autoantibody
responses.28,30
Kontoyiannis et al.25 specifically evaluated the role of
TNFa reduction in the (NZBNZW)F1 lupus model. They
showed that first generation offspring of NZB mice crossed
with TNFa-deficient mice show an autoimmune phenotype
similar to the (NZBNZW)F1 mice. That is, NZB-TNFanull
mice present with autoantibodies and spontaneous glomer-
ulonephritis, however, with a delay and a milder phenotype
compared with (NZBNZW)F1 mice, suggesting an addi-
tional contribution of the NZW background. The authors
speculate that the low TNFa production in these mice may
facilitate the switch from IgM to pathogenic IgG anti-dsDNA
antibody production and significantly increase the prolif-
erative response of B cells. In the MRL-lpr/lpr SLE murine
model, TNFa may also have an initial immunosuppressive
role. When these mice are crossed with TNFR1-deficient
mice, they present with much more severe autoimmune
disease and glomerulonephritis, possibly because of a
compensatory decrease in activation-induced T-cell apopto-
sis.131 Thus, TNFa plays an important immunomodulating
role in the initiation phase of the two models of lupus
nephritis with lower production of TNFa triggering a
breakage of tolerance in genetically susceptible animals.
In humans, TNFa may also play an initial immunomo-
dulatory role. TNFa and its receptor polymorphisms in SLE
patients may give some insights into the role of TNFa in
lupus nephritis. For instance, HLA-DR2-positive individuals
are prone to autoimmune diseases and, in particular, lupus
nephritis. This HLA genotype is correlated with lupus
nephritis development, which in turn is associated with a
lower production of TNFa.153 The most frequently reported
polymorphism of TNFa is -308 A/G, which is associated with
an increase in susceptibility to SLE, in particular in
Caucasians, as shown in a recent meta-analysis.154 This
polymorphism may be functionally associated with a slight
increase in the promoter activity and thus TNFa production,
which may explain the enhanced end-organ damage observed
in these patients. By contrast, another polymorphism of
TNFa promoter (863 C/A) is associated with protection
from SLE,152 despite the fact that it too induces an increase in
activity of the promoter. In this case, it may be speculated
that it is linked to the immunosuppressive role of TNFa in
the early phase of SLE. Another frequently reported
polymorphism is the TNFR2 M196R, which is associated
with chronic inflammatory disorders, such as familial
rheumatoid arthritis and ulcerative colitis.155 This functional
polymorphism modulates the signaling properties of TNFR2
by decreasing its ability to recruit TRAF2 and activate the
NFkB pathway; this subsequently enhances TNFR1-induced
apoptosis.156 TNFR2 M196R has been recently associated
with SLE in the Japanese patients,155,157 but this association
was not confirmed in two transmission disequilibrium test
studies that included mainly Caucasian families.158,159 The
TNFR2 M196R polymorphism functional significance may
thereby be specific to ethnicity.
In addition to its immunosuppressive roles, TNFa is
clearly implicated in end-organ tissue injury in SLE patients
and, in particular, lupus nephritis. In both mice160–162 and
humans,56,57,163 TNFa is highly expressed in the kidney
during lupus nephritis and SLE patients typically present
with high serum levels of TNFa and soluble TNFRs that
correlate with disease activity.36,164–166 Moreover, recombi-
nant TNFa administration in MRL-lpr/lpr mice167 after the
onset of the nephritis in (NZBNZW)F1 mice161 is
associated with increased renal damage. Similarly, TNFa
blockade suppresses SLE induced experimentally in mice by
the injection of a human DNA autoantibody,168 as well as
lung inflammation or arthritis induced in lupus-prone
mice.169,170
A few case reports and one small open-label study have
shown promising clinical improvement in lupus nephritis in
about two-third of the patients treated with infliximab, a
commercial chimeric monoclonal anti-TNFa antibody.36,37
Infliximab treatment was, however, associated with increased
autoantibody titer, but was not coupled with SLE flares and
resolved after interruption of the treatment.37,171 The clinical
improvement can be easily explained by the quick potent
inhibition of the proinflammatory properties of TNFa
leading to renal tissue injury. To avoid emergence of clinically
significant autoimmune disorders induced by anti-TNFa
treatments, Aringer et al.36 propose a short four dose-
inducing treatment of TNFa blockade associated with
azathioprine. They have recently started the first double-
blind placebo-controlled trial evaluating this protocol in
patients with corticosteroid-resistant membranous lupus
nephritis.172
ANCA-associated vasculitis nephritis
TNFa is largely implicated in ANCA-associated vasculitis
nephritis. Its expression is upregulated in the glomeruli,
interstitia and, to a lesser extent, in tubular cells in renal
biopsies of patients with Wegener’s granulomatosis or
microscopic polyangiitis.58 In vasculitis, expression of TNFa
is also increased in peripheral blood mononuclear cells,173
and circulating levels of soluble TNFR1 and TNFR2 are
highly increased in MPO-ANCA-associated vasculitis
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patients.174 Their peripheral blood neutrophils also express
higher amounts of both membranous receptors.174 A
polymorphism of the promoter of TNFa (238 G/A), which
is associated with a higher cytokine level, is more frequent in
Wegener’s granulomatosis patients and may contribute to
disease susceptibility,175 thus providing a clue to the
functional relevance of TNFa in this disease.
In vasculitis pathogenesis, TNFa is critically implicated
in the priming of neutrophils and monocytes, inducing
their expression of MPO and proteinase-3 at the surface
through p38-MAPK- and ERK-dependent pathways.176
ANCA then binds the exposed autoantigens and, after
crosslinking with Fcg receptors, triggers neutrophil
oxidative burst, degranulation, cytokines production, and
subsequent inflammatory events that eventually lead to
endothelium injury and end-organ tissue damage, such
as alveolar hemorrhage and pauci-immune crescentic
glomerulonephritis (reviewed in177).
The proinflammatory role of TNFa in vasculitis in vivo
has been explored in experimental models of ANCA. For
instance, in an experimental autoimmune vasculitis model in
rats,178,179 the administration of anti-TNFa antibody dra-
matically reduced glomerular lesions (near absence of
crescentic lesions in treated animals) as well as interstitial
nephritis, hematuria, albuminuria, and alveolar hemor-
rhage.178 Besides the role of TNFa on neutrophils, this
beneficial effect of TNFa blockade may be also explained by
the important role of TNFa in leukocyte–endothelial cell
interactions leading to endothelial cell injury in vasculitis as
shown by intravital microscopy in this model.178,179 Another
ANCA-associated vasculitis model has been developed in
mice: splenocytes or anti-MPO antibodies raised in MPO-
deficient mice are transferred to naive animals, which
consequently develop pauci-immune necrotizing glomerulo-
nephritis.180 Concomitant administration of LPS in this
model is associated with more severe glomerular injury that
is counteracted by anti-TNFa treatment. This supports
thereby an important role for TNFa in ANCA-associated
vasculitis and suggests a potential benefit for TNFa blockade
in treatment of these diseases.181 Indeed, encouraging
beneficial results of open-label administration of infliximab
in ANCA-associated vasculitis patients have been re-
ported.31–33 However, a recent randomized controlled trial
evaluating etanercept in Wegener’s granulomatosis patients
showed no benefit.34 As discussed further, this last study does
not rule out a potential benefit of TNFa blockade in
vasculitis, but does indicate the need for more controlled
trials.
Kidney allograft rejection
As allograft rejection is mediated by both innate and adaptive
immune responses, it is not surprising that TNFa is largely
implicated in graft failure (review in182). Indeed, TNFa has
been implicated in kidney allograft rejection for many years,
but its specific role in proinflammatory events leading to
graft injury is not fully understood. In rat experimental
models, TNFa mRNA expression is upregulated in tissue
samples during both acute and chronic kidney allograft
rejection.183,184 In humans, TNFa expression is also increased
in renal tissue during acute rejection.185–187 Plasmatic and
urinary TNFa levels are also significantly elevated,188,189 as
well as circulating soluble TNFR1 and TNFR2.190 Interest-
ingly, elevation of TNFa circulating level may be predictive of
transplant rejection and was observed 2 days before the
clinical manifestations in one report.191 In chronic allograft
nephropathy, TNFa is also upregulated186,192 and may be
specifically implicated in the intimal hyperplasia of arterial
walls observed in late graft failure.192,193
In acute rejection, a prominent role of TNFa–TNFR2 is
suggested by a detailed study in which expression of TNFa
and its receptors in biopsy samples was compared between
normal and acute rejected kidneys.45 By immunofluorescence
and in situ mRNA hybridization, TNFa and TNFR2 were
found to be absent in normal kidney, but both were
consistently upregulated in the tubular epithelial cells while
remaining undetectable in glomeruli during acute rejection.
Furthermore, their level of expression correlated with the
severity of the rejection episode. By contrast, TNFR1 was
expressed in normal glomeruli, predominantly in endothelial
cells, but became virtually undetectable during acute renal
rejection.45
A functional role for TNFa in kidney allograft acute
rejection may be inferred from a nonhuman primate allograft
model. Administration of recombinant human TNFR:Fc
fusion protein significantly delayed the onset of rejection and
prolonged the overall allograft survival.194 Different poly-
morphisms of TNFa also suggest its proinflammatory role in
graft rejection. Indeed, in kidney transplant recipients, the
TNFa promoter polymorphism 308 G/A, associated with a
high cytokine level,195 is frequently reported to be correlated
with an increased risk of acute renal allograft rejection.196–203
There are, however, some reports failing to show such an
association.204,205 In chronic allograft nephropathy, this
polymorphism has also been recently associated with an
increased risk for disease,206 although this has not been
confirmed in other reports.207,208 Most of these studies have,
however, assessed the polymorphisms of the graft recipients,
whereas the local production of TNFa by donor tissue may
also play a role. Nevertheless, one recent report did assess the
potential link between the TNFa 308 G/A polymorphism in
both recipients and donors. Interestingly, an association was
observed between allograft rejection and recipient high
producer 308 A polymorphism, whereas no correlation
was found with the donor genotype.209 To date, there are no
data on the efficacy of anti-TNFa treatments in kidney
allograft recipients. One open-label single-center clinical trial
has been recently initiated, but results have not yet been
published.182
TNFa-NEUTRALIZING TREATMENTS IN KIDNEY DISEASES
Given that TNFa shows both proinflammatory and im-
munosuppressive properties, it is not simple to predict the
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effect of anti-TNFa treatments. Such treatments show great
benefit in inflammatory diseases such as rheumatoid
arthritis6,7 and Crohn’s disease,8 but autoimmunity has been
observed in some of the treated patients, and in other cases,
such as sepsis or multiple sclerosis, inefficiency and potential
harmful effects have been noted, thus raising concerns about
the safety of these treatments in general.
Moreover, the actual anti-TNFa treatments are not
equivalent and may thus explain the different outcomes
observed.210 The chimeric monoclonal anti-TNFa antibody
infliximab, as well as the newer humanized monoclonal anti-
TNFa antibody adalimumab, is able to induce cell lysis when
bound to membrane-bound TNFa, for example, in macro-
phages.211,212 By contrast, etanercept, a recombinant protein
of TNFR2 fused with the Fc domain of human immunoglo-
bulin G1 (IgG1), primarily binds soluble TNFa versus
membrane-bound TNFa and does not directly induce cell
apoptosis. In contrast with infliximab, it is also able to bind
lymphotoxin-a.15,210 This biochemical difference may ac-
count for the variable efficiency of etanercept and infliximab
observed in the clinic, especially in granulomatosis diseases:
although both medications are efficient in rheumatoid
arthritis patients, etanercept has no beneficial effect in
Crohn’s disease,213 which is in contrast with the reported
efficiency of both infliximab8,214 and adalimumab215 in
treatment of Crohn’s disease. Similarly, in the recent
double-blind controlled study, Wegener’s Granulomatosis
Etanercept Trial (WGET), etanercept failed in the treatment
of Wegener’s disease,34 which is in contrast with many reports
and one small open-label study that observed a beneficial
effect of infliximab in this disease.31–33 These results highlight
the need to evaluate the efficacy of each anti-TNFa regimen
in each inflammatory disease.
Compared with traditional immunosuppressive drugs,
anti-TNFa treatments are generally safe. Therefore, it is
tempting to apply these treatments in many inflammatory
conditions, including kidney diseases. However, some serious
side effects of anti-TNFa treatment should be considered. For
example, aside from the autoimmune responses as detailed in
this review and the increased incidence of bacterial infections
and activation of latent tuberculosis infection in anti-TNFa-
treated patients,15,216 another concerning safety issue is the
higher incidence of lymphomas217,218 and potentially solid
tumors during anti-TNFa treatment, which has been
attributed to a possible decrease in immunosurveillance.
For instance, in a post hoc analysis of Wegener’s Granuloma-
tosis Etanercept Trial (see further), six cases of solid
malignancies among 89 treated patients (7%) have been
reported.219 Moreover, co-treatment with cyclophosphamide
may increase this risk, as well as the underlying disease, such
as rheumatoid arthritis, which may itself confer a higher
malignancy risk. This increased frequency of tumors is
however controversial35 and a large cohort study of 4160
rheumatoid arthritis patients treated with TNFa antagonists
did not show any increased risk of lymphomas after
adjustment for age, sex, and disease duration.220
There is currently no validated indication of anti-TNFa
treatments in kidney diseases. However, as mentioned
above, there are growing emerging data suggesting a
potential benefit of infliximab in lupus nephritis. Moreover,
despite the negative results of the etanercept in the WGET
trial, open label studies and case reports consistently suggest a
beneficial effect of infliximab in Wegener’s granulomatosis.
Given the known differences in the mechanisms of
action between etanercept and anti-TNFa monoclonal anti-
body, beneficial effects of anti-TNFa antibodies in vasculitis
may still be expected. Controlled trials evaluating the
efficiency of infliximab and adalimumab in both vasculitis-
associated nephritis and lupus nephritis are urgently
required. At least two clinical trials are ongoing in patients
with lupus nephritis, and the results of a recent randomized
clinical trial in ANCA-associated vasculitis are expected
(Table 2).38,172,221
SUMMARY
TNFa biology in inflammatory diseases is complex as TNFa
shows both proinflammatory and immunoregulatory proper-
ties. Therefore, its contribution to each inflammatory
condition may differ, as illustrated by anti-TNFa treatments,
which provide great benefits for rheumatoid arthritis
patients, but in contrast enhance autoimmunity in patients
with multiple sclerosis. In kidney diseases, experimental data
suggest that TNFa also exhibits both proinflammatory and
immunosuppressive functions. Nonetheless, some studies
have suggested benefits of anti-TNFa treatments in renal
inflammation, although this needs to be convincingly shown
in randomized controlled trials. This may not be an easy task
because of the limited and heterogeneous patient population
for diseases such as ANCA-associated vasculitis or SLE and
the variable involvement of the kidney in some of these cases.
Paradoxically, as anti-TNFa may lead to the induction in
autoimmunity, including lupus syndrome and glomerulone-
phritis in a subset of patients, new approaches for treatment
of renal inflammatory and autoimmune diseases may be
required. We postulate that new strategies should focus on its
two receptors, which relay the multiple functions of TNFa
through distinct intracellular signals. For example, in kidney
diseases, TNFR2 may be the preferred target, as its expression
is induced during renal inflammation in a renal compart-
ment-specific manner and its deficiency in mice confers
significant protection from renal tissue injury in autoim-
mune disease models.75,103,157,222 Moreover, its immunosup-
pressive functions may be redundant with TNFR1. It is noted
that TNFR1 deficiency enhances disease in the MRL-lpr/lpr
SLE model.131 Thus, the specific blockade of TNFR2, which
preserves TNFR1 function, may aid in balancing the
proinflammatory and immunosuppressive functions of
TNFa in renal diseases. Along these lines, identifying key
signaling events downstream specifically of TNFR2 may
reveal additional therapeutic targets for modulating TNFR2
function.
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